Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Gottschalk

Pediatric Endocrinology San Diego, CA Medical Doctor

NPI 1033280888 CMS profile 183244

8110 Birmingham Way, San Diego, CA 92123

Open in the dashboard

General payments

$16,661

133 records reported · program years 2019–2025

Research payments

$8,325

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,344,656 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Gottschalk of San Diego, CA is reported in the CMS Open Payments database as having received $16,661 across 133 general payments and $8,325 in research payments paid to them. Separately, studies naming them as principal investigator received $2,344,656 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $245 7
2024 General $343 16
2023 General $1,999 28
2022 General $2,395 5
2021 General $2,121 6
2020 General $5,616 10
2020 Research $255 1
2019 General $3,942 61
2019 Research $8,070 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Gottschalk
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Michael Gottschalk were reported at $245. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Michael Gottschalk Pediatric Endocrinology median Middle half National median
2019 $3,942 $196 $68–$845 $163
2020 $5,616 $124 $37–$722 $114
2021 $2,121 $134 $35–$691 $132
2022 $2,395 $177 $47–$726 $149
2023 $1,999 $236 $75–$887 $160
2024 $343 $259 $91–$979 $164
2025 $245 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $6,822 10 payments
  2. Rhythm Pharmaceuticals, Inc. $2,445 3 payments
  3. Ipsen Biopharmaceuticals, Inc $2,257 10 payments
  4. Eli Lilly and Company $1,385 6 payments
  5. Sanofi-Aventis U.S. LLC $742 4 payments
  6. Mannkind Corporation $728 4 payments
  7. Novo Nordisk Inc $571 26 payments
  8. Dexcom, Inc. $283 13 payments
  9. Ferring Pharmaceuticals Inc. $260 10 payments
  10. AbbVie, Inc. $222 10 payments
  11. Other $946 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,520 4 payments
  2. Food and Beverage $3,071 112 payments
  3. Travel and Lodging $2,751 9 payments
  4. Education $2,180 3 payments
  5. Honoraria $1,350 1 payment
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $670 2 payments
  7. Gift $119 2 payments
Products named General payments · program years 2019–2025
  1. Welchol $6,822 10 payments
  2. INCRELEX $2,257 10 payments
  3. HUMALOG $1,328 4 payments
  4. TZIELD $742 4 payments
  5. AFREZZA $728 4 payments
  6. Imcivree $400 1 payment
  7. Dexcom G6 Transmitter $260 12 payments
  8. ZOMACTON $260 10 payments
  9. Sogroya $248 11 payments
  10. Norditropin $222 10 payments
  11. Other $1,675 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $8,325 2 payments

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record